Home » Commercial Planning

Thought Leadership

CBPartners’ Commercial Planning practice will never simply deliver results – facts and findings are taken to the next level for meaningful insights, comparative revelation, and strategic guidance.

Showing 5 of 15 posts
Non-traditional Players in Healthcare Part II
September 22, 2021 | Blogs

Part II: Non-Traditional Players Attempting Entry into the Healthcare Sector

In part two of this series about non-traditional players in the healthcare space, CBPartners dives into one company’s (Walmart) recently established partnership with a traditional pharmaceutical company (Novo Nordisk) to investigate the larger ramifications of these new entrants for key stakeholders – patients, the pharmaceutical industry, and their traditional competition.

Image of Verily's office
August 30, 2021 | Blogs

Verily to Acquire SignalPath, Expanding the Company’s Clinical Research Capabilities

Verily recently announced its first major acquisition, a software platform known as SignalPath. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform.

October 20, 2020 | Blogs

Digital Therapeutics as Digital Companions: Models for Effective Pharma Partnerships

Pharma and biotech companies should be prepared to make long-term investments in capability building, market development, and evidence generation to maximize the value of digital companions.

September 17, 2020 | Blogs

Hitting the Mark: Lessons Learned From Blockbuster Drugs That Missed or Exceeded Analyst Expectations

Pharmaceutical products can both exceed and fall short of blockbuster sales expectations by considerable margins which can be a result of a number of reasons. Some of these include the value of first-to-market dynamics, supporting real-world evidence to gain a competitive edge, and continual investment in trials for follow-on indications to improve life cycle management.

Decorative image of blog post depicting biopharma
September 8, 2020 | Blogs

How Do Companies Spend the Revenue Generated from Blockbuster Drugs? A Closer Look at Vertex and Gilead

Blockbuster drugs can generate billions of dollars for pharmaceutical manufacturers, but what can be learned from the investment strategies that GILEAD and VERTEX pursued from the revenue that they generated from SOVALDI and ORKAMBI respectively?